The nation of Zimbabwe has rejected a significant US health deal worth $367m (272 million pounds) spanning five years due to Washington's insistence on sensitive biological samples.
This move came to light after a official document dated December was disclosed, which showed Head of State Emmerson Mnangagwa deemed the agreement was "lopsided".
A government spokesperson later stated that the United States was requesting health data for research and profit but was not willing to share the resulting advantages from future treatments.
"We must now begin the challenging and unfortunate task of scaling back our health aid in Zimbabwe," remarked US ambassador to Zimbabwe Pamela Tremont in a statement.
Her embassy said the United States had furnished more than $1.9bn as health assistance to Zimbabwe during the past twenty years.
A medical body in Zimbabwe has urged continued talks to reach a deal agreeable to both sides so the country's critical HIV programme can be sustained.
Wider Implications
This rejection follows a similar case in neighbouring Kenya, where a court blocked a similar deal with the US following concerns were filed about the security of Kenyans' health data.
After returning to office recently, US President Donald Trump has reduced foreign aid and closed the key foreign aid agency.
The agency had managed assistance for the American government, but Trump stated its spending was "inefficient" and his government was pursuing government-to-government agreements to boost transparency and responsibility.
As per statements, Sixteen African countries have so far agreed to these new health pacts, constituting more than $18.3bn in new funding.
Details of the Declined Deal
The money for Zimbabwe would have funded "combating HIV/Aids, tuberculosis, malaria, healthcare for mothers and children, and preparing for epidemics".
"It is our view this collaboration might have yielded significant benefits for the people of Zimbabwe, particularly the 1.2 million men, women and children currently receiving antiretroviral therapy via American-funded initiatives," the Ambassador said.
However, official spokesman Nick Mangwana said the arrangement was "asymmetrical".
"The proposal required Zimbabwe to surrender its genetic material and health information indefinitely, without any equivalent promise of benefiting from any medical innovations – like vaccines, diagnostics, or treatments – that could result from that provided information," Mangwana explained.
"In essence, our country would provide the raw materials for scientific discovery with no assurance that the resulting innovations would be available to our people if a new disease outbreak emerge."
Sovereignty and Global Health
He also pointed out that the US's withdrawal from the global health body and its pursuit of bilateral health agreements were upending structures already set up via the international organization.
The spokesperson cited its Pathogen Access and Benefit Sharing scheme designed to manage potential pandemics.
"This system is intended to guarantee that when a country contributes its information, the benefits – including vaccines and treatments – are shared equitably, not commercialised solely by those with the funds to create them."
Zimbabwe's reservations over the US deal "should not be misconstrued as opposition to America," he added.
"We are open to further dialogue with our US partners on how subsequent co-operation might be designed in a manner that honours the sovereignty and interests of each country."
Health Experts Reaction
Medical experts expressed it acknowledged the government's concerns, but suggested that talks need to persist given that much of the nation's Aids initiatives relied on foreign aid.
"Where technical issues arise, including those involving data governance or implementation frameworks, these can frequently be addressed via technical clarification and mutually agreed protections," the group added.
This impasse highlights the continuing challenges between accepting crucial foreign assistance and protecting local interests in an ever more data-driven world.